• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Tissue plasminogen activator reduces neurological damage after cerebral embolism.

作者信息

Zivin J A, Fisher M, DeGirolami U, Hemenway C C, Stashak J A

出版信息

Science. 1985 Dec 13;230(4731):1289-92. doi: 10.1126/science.3934754.

DOI:10.1126/science.3934754
PMID:3934754
Abstract

Intravenous administration of tissue plasminogen activator immediately after the injection of numerous small blood clots into the carotid circulation in rabbit embolic stroke model animals caused a significant reduction in neurological damage. In vitro studies indicate that tissue plasminogen activator produced substantial lysis of clots at concentrations comparable to those expected in vivo, suggesting that this may be the mechanism of action of this drug. Drug-induced hemorrhages were not demonstrable. Tissue plasminogen activator may be of value for the immediate treatment of embolic stroke.

摘要

相似文献

1
Tissue plasminogen activator reduces neurological damage after cerebral embolism.
Science. 1985 Dec 13;230(4731):1289-92. doi: 10.1126/science.3934754.
2
Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke.组织型纤溶酶原激活剂。实验性栓塞性中风后神经损伤的减轻。
Arch Neurol. 1988 Apr;45(4):387-91. doi: 10.1001/archneur.1988.00520280033012.
3
Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected].兔栓塞性中风后用组织纤溶酶原激活剂或链激酶治疗后的脑出血发生率[已修正]
Stroke. 1990 Nov;21(11):1589-93. doi: 10.1161/01.str.21.11.1589.
4
Evaluation of recombinant tissue plasminogen activator in embolic stroke.重组组织型纤溶酶原激活剂在栓塞性中风中的评估。
Neurosurgery. 1989 Mar;24(3):355-60. doi: 10.1227/00006123-198903000-00008.
5
Optimized thrombolysis of cerebral clots with tissue-type plasminogen activator in a rabbit model of embolic stroke.在兔栓塞性中风模型中使用组织型纤溶酶原激活剂对脑血凝块进行优化溶栓。
J Pharmacol Exp Ther. 1993 Jan;264(1):67-73.
6
Tissue-type plasminogen activator improves neurological functions in a rat model of thromboembolic stroke.组织型纤溶酶原激活剂可改善血栓栓塞性中风大鼠模型的神经功能。
Stroke. 1994 Feb;25(2):451-6. doi: 10.1161/01.str.25.2.451.
7
A comparison of intra-arterial and intravenous tissue-type plasminogen activator on autologous arterial emboli in the cerebral circulation of rabbits.动脉内与静脉内注射组织型纤溶酶原激活剂对兔脑循环中自体动脉栓子作用的比较。
Stroke. 1994 Mar;25(3):651-5; discussion 656. doi: 10.1161/01.str.25.3.651.
8
Reduction of infarct volume and mortality by thrombolysis in a rat embolic stroke model.在大鼠栓塞性中风模型中,溶栓可减少梗死体积并降低死亡率。
Stroke. 1992 Aug;23(8):1167-73; discussion 1174. doi: 10.1161/01.str.23.8.1167.
9
Influence of tissue plasminogen activator and heparin on cerebral ischemia in a rabbit model.组织型纤溶酶原激活剂和肝素对兔脑缺血模型的影响。
Stroke. 1992 Jun;23(6):883-8. doi: 10.1161/01.str.23.6.883.
10
Influence of a 'brain protector' drug 21-amino steroid on the effects of experimental embolic stroke treated by thrombolysis.“脑保护剂”药物21-氨基类固醇对溶栓治疗实验性栓塞性中风效果的影响。
Neurol Res. 1995 Dec;17(6):423-5.

引用本文的文献

1
Ischemic stroke and intervention strategies based on the timeline of stroke progression: Review and prospects.基于卒中进展时间线的缺血性卒中和干预策略:综述与展望
Acta Pharm Sin B. 2025 Sep;15(9):4543-4581. doi: 10.1016/j.apsb.2025.07.026. Epub 2025 Jul 23.
2
Inhibition of proprotein convertase SKI-1 prevents blood vessel alteration after stroke.抑制前蛋白转化酶SKI-1可预防中风后的血管改变。
Nat Cardiovasc Res. 2025 Aug 26. doi: 10.1038/s44161-025-00691-5.
3
Behavioral tests to assess short- and long-lasting sensorimotor deficits following transient focal cerebral ischemia in rodents.
评估啮齿动物短暂局灶性脑缺血后短期和长期感觉运动功能障碍的行为测试。
Pharmacol Rep. 2025 Jul 3. doi: 10.1007/s43440-025-00747-0.
4
Sex Differences in the Dual Antiplatelet Therapy Versus Alteplase for Patients with Minor Nondisabling Acute Ischemic Stroke: A Secondary Analysis of the ARAMIS Study.双重抗血小板治疗与阿替普酶治疗轻度非致残性急性缺血性卒中患者的性别差异:ARAMIS研究的二次分析
CNS Drugs. 2024 Aug;38(8):649-659. doi: 10.1007/s40263-024-01096-x. Epub 2024 May 28.
5
α-Phenyl--Butylnitrone and Analogous α-Aryl--alkylnitrones as Neuroprotective Antioxidant Agents for Stroke.α-苯基-叔丁基硝酮及类似的α-芳基-叔烷基硝酮作为中风的神经保护抗氧化剂
Antioxidants (Basel). 2024 Apr 7;13(4):440. doi: 10.3390/antiox13040440.
6
Neutralizing RGMa with Elezanumab Promotes Cerebroprotection and Recovery in Rabbit Middle Cerebral Artery Occlusion.用 Elezanumab 中和 RGMa 可促进兔大脑中动脉闭塞的脑保护和恢复。
Transl Stroke Res. 2024 Aug;15(4):805-817. doi: 10.1007/s12975-023-01164-2. Epub 2023 Jun 16.
7
The Vessel Has Been Recanalized: Now What?血管再通:接下来该怎么办?
Neurotherapeutics. 2023 Apr;20(3):679-692. doi: 10.1007/s13311-023-01367-3. Epub 2023 Apr 4.
8
Fibrinolysis: an illustrated review.纤维蛋白溶解:图文并茂的综述。
Res Pract Thromb Haemost. 2023 Feb 17;7(2):100081. doi: 10.1016/j.rpth.2023.100081. eCollection 2023 Feb.
9
Fifty Years of Acute Ischemic Stroke Treatment: A Personal History.《急性缺血性脑卒中治疗的五十年:个人史》
Cerebrovasc Dis. 2021;50(6):666-680. doi: 10.1159/000519843. Epub 2021 Oct 14.
10
Animal models of stroke.中风的动物模型。
Animal Model Exp Med. 2021 Sep 15;4(3):204-219. doi: 10.1002/ame2.12179. eCollection 2021 Sep.